MetabolicFDA Approved

Pramlintide (Symlin)

Subcutaneous injection (before meals)

Overview

A synthetic analog of amylin (islet amyloid polypeptide), a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells. Pramlintide has three proline substitutions that prevent amyloid fibril formation while retaining amylin receptor activity.

Mechanism of Action

It slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety via area postrema activation, complementing insulin therapy in diabetes management..

Research Summary & Key Findings

FDA-approved in 2005 as adjunct to insulin therapy in type 1 and type 2 diabetes. Clinical trials showed 0.3-0.6% additional HbA1c reduction and 1-2 kg weight loss when added to insulin. Reduces postprandial glucose excursions by 50% through delayed gastric emptying and glucagon suppression.

Clinical Status

FDA Approved

Pramlintide (Symlin) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (before meals)

Related Peptides in Metabolic

Find a Provider

Find a verified provider who offers Pramlintide (Symlin) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Pramlintide (Symlin).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.